Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a synthetic biology company that entered the public markets in September 2021 through a SPAC merger with Soaring Eagle Acquisition Corp, sponsored by Soaring Eagle Acquisition Partners LLC. Operating in the biotechnology sector, the Boston-based firm provides cell programming and biological platform services to customers across pharmaceutical, agriculture, and industrial end markets. Ginkgo filed its most recent Form 10-Q with the SEC on August 6, 2026, continuing its quarterly reporting obligations as a post-merger public company. For comprehensive filing history, financials, and SPAC deal analytics on Ginkgo Bioworks and the broader de-SPAC universe, sign up for full data access at SpacDesk.